Tophaceous gout in patients with systemic lupus erythematosus.
Coexistent gout and systemic lupus erythematosus (SLE) has been reported rarely, below the expected incidence even when adjusted for the discordance of age and sex of the affected populations. It is possible that SLE prevents expression of gout, or vice-versa. Review of the reported cases suggests that SLE is likely to be inactive and serum complement normal when gout is active. Lack of awareness of the possibility of gout and concurrent treatment with corticosteroids and nonsteroidal anti-inflammatory drugs may prevent recognition of gout in many patients with SLE.
D000328:Adult; D003460:Crystallization; D005260:Female; D006073:Gout / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D011859:Radiography; D014527:Uric Acid / Q000378:metabolism*
D014527:Uric Acid; D011241:Prednisone; D007213:Indomethacin